Sustained Response on Sequential Anti-fgfr Therapy in Metastatic Gall Bladder Cancer - a Case Report and Literature Review

Abstract

Abstract Advanced gall bladder cancer (aGBC) is an aggressive disease with no consensus on treatment options beyond first line chemotherapy. We report a case of an elderly male with FGFR2 altered advanced adenocarcinoma of the gallbladder who failed two prior lines of chemotherapy but had sustained response and stable disease on sequential FGFR directed targeted therapy. This treatment was based on comprehensive genomic profiling by next-generation sequencing revealed FGR2 alteration. Sequential anti-FGFR tyrosine kinase inhibitors was initiated as a treatment of choice. The patient tolerated the sequential targeted therapy very well and had a sustained response and stable disease with 5 years of survival. Our study demonstrates that aGBC with FGFR alteration can be managed on anti-FGFR therapy for prolonged periods of time, with improved survival. The study revealed a FGFR-directed therapeutic as a viable treatment option in these patients.